ESR1 and breast carcinoma: Results from early in vitro and in vivo studies have demonstrated that treatment with PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal ER-positive human breast cancer cell lines in vitro [57].